Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by PTBaileyon Jan 25, 2022 9:04pm
93 Views
Post# 34360693

RE:RE:Game Changer - Claritas Brief Part 4

RE:RE:Game Changer - Claritas Brief Part 4

"What is a "paid Claritas pumpert" is it someone who has access to confidential information....and from making use of such information in trading in the company’s securities before the information has been fully disclosed to the public... in a reasonable period of time for dissemination of the information has passed....pumpert?"

I would imagine that a "paid pumper" has been given information to pump that is from the management, Bob. But since you refer to paid pumpers so much you must know what they are.

In any case, explaining what went on with the Ethics Committee and Salzman is hardly material information so you never ever would have heard about it in any Press Release. A person would be truly dense to not get that when the information is put right in front of them and they still refuse to comprehend it. It is completly understandable why they wouldn't have any shares.

You also seem to go into anal overdrive on misspelled words, try reading the context that helps. And so you don't have to waste time being the spelling police in the future I put no effort into making sure everything is spelled correctly when responding to you compared to a writing proposal for client or masters thesis. So please stop stresing over spelling, relax.

<< Previous
Bullboard Posts
Next >>